litlas
Log inCreate account

Éric Raymond

Active 1996–2025

Also published as
Eric Raymond
102
Papers
24,837
Citations
79
h-index
101
i10-index

Citations

Citations per year for Éric Raymond1984: 2 citations1994: 1 citations1996: 1 citations1998: 15 citations1999: 32 citations2000: 46 citations2001: 52 citations2002: 87 citations2003: 110 citations2004: 115 citations2005: 157 citations2006: 145 citations2007: 186 citations2008: 208 citations2009: 247 citations2010: 227 citations2011: 211 citations2012: 186 citations2013: 248 citations2014: 258 citations2015: 254 citations2016: 247 citations2017: 254 citations2018: 227 citations2019: 744 citations2020: 743 citations2021: 697 citations2022: 446 citations2023: 292 citations2024: 447 citations2025: 237 citations2026: 3 citations1985–1993: no citations, so these years are not shown1995: no citations, so this year is not shown1997: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,382 citing papers, 23.5% of this breakdownChina: 1,114 citing papers, 11% of this breakdownItaly: 715 citing papers, 7.1% of this breakdownFrance: 608 citing papers, 6% of this breakdownUnited Kingdom: 551 citing papers, 5.4% of this breakdownGermany: 506 citing papers, 5% of this breakdownSpain: 351 citing papers, 3.5% of this breakdownJapan: 321 citing papers, 3.2% of this breakdownNetherlands: 287 citing papers, 2.8% of this breakdownCanada: 269 citing papers, 2.6% of this breakdownIndia: 258 citing papers, 2.5% of this breakdownSouth Korea: 239 citing papers, 2.4% of this breakdown
0%23.5%Other 25%

Institutions

Fields

  • Medicine64.4%
  • Biochemistry, Genetics and Molecular Biology24.9%
  • Immunology and Microbiology3.9%
  • Chemistry1.2%
  • Materials Science1.1%
  • Pharmacology, Toxicology and Pharmaceutics0.9%
  • Other3.6%

Topics

  • Neuroendocrine Tumor Research Advances4.1%
  • Hepatocellular Carcinoma Treatment and Prognosis4%
  • Lung Cancer Research Studies3.6%
  • PI3K/AKT/mTOR signaling in cancer2.7%
  • Pancreatic and Hepatic Oncology Research2.5%
  • Cancer Mechanisms and Therapy2.2%
  • Other80.9%

Coauthors

All papers

Open in search
  1. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study

    Authors: Jianming Xu, Ken Kato, Eric Raymond, Richard Hubner, Yongqian Shu, Yueyin Pan, Sook Ryun Park, Lu Ping, Yi Jiang, Jingdong Zhang, Xiaohong Wu, Yuanhu Yao, Lin Shen, Takashi Kojima, Evgeny Gotovkin, Ryu Ishihara, Lucjan Wyrwicz, Eric Van Cutsem, Paula Jiménez‐Fonseca, Chen‐Yuan Lin, Lei Wang, Jingwen Shi, Liyun Li, Harry H. Yoon - The Lancet Oncology 2023 cited by 291

  2. Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

    Authors: Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul, Yung‐Jue Bang, Ivan Borbath, Catherine Lombard‐Bohas, Juan W. Valle, Peter Metrakos, Denis Smith, Aaron I. Vinik, Jen‐Shi Chen, Dieter Hörsch, Pascal Hammel, Bertram Wiedenmann, Eric Van Cutsem, Shem Patyna, Dongrui R. Lu, C. Blanckmeister, Richard C. Chao, Philippe Ruszniewski - New England Journal of Medicine 2011 cited by 2,547

  3. Targeting the TGFβ pathway for cancer therapy

    Authors: Cindy Neuzillet, Annemilaï Tijeras‐Raballand, Romain Cohen, Jérôme Cros, Sandrine Faivre, Éric Raymond, Armand de Gramont - Pharmacology & Therapeutics 2014 cited by 615

  4. GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions

    Authors: Sonia Brun, Eloïne Bestion, Éric Raymond, Firas Bassissi, Zuzana Macek Jílková, Soraya Mezouar, Madani Rachid, Marie Novello, Jennifer Tracz, Ahmed Hamaï, Gilles Lalmanach, Lise Vanderlynden, Raphaël Legouffe, Jonathan Stauber, Thomas Schubert, Maximilian G. Plach, Jérôme Courcambeck, Cyrille Drouot, Guillaume Jacquemot, Cindy Serdjebi, Gaël S. Roth, Jean‐Pierre Baudoin, Christelle Ansaldi, Thomas Decaens, Philippe Halfon - Autophagy 2021 cited by 86

  5. Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids

    Authors: M. Caplin, Éric Baudin, Piero Ferollà, Pier Luigi Filosso, Mariano Garcı́a-Yuste, Eric Lim, Kjell Öberg, Giuseppe Pelosi, Aurel Perren, Roberta Rossi, William D. Travis, D.K. Bartsch, Jaume Capdevila, Frederico Costa, Jarosław B. Ćwikła, Wouter W. de Herder, Gianfranco Delle Fave, Barbro Eriksson, Massimo Falconi, Diego Ferone, David J. Gross, Ashley Grossman, Tetsuhide Ito, Robert T. Jensen, Gregory Kaltsas, Fahrettin Keleştimur, Réza Kianmanesh, Ulrich Knigge, Beata Kos‐Kudła, Eric P. Krenning, Emmanuel Mitry, M. Nicolson, Juan Manuel O’Connor, Dermot O’Toole, Ulrich-Frank Pape, Marianne Pavel, John Ramage, Éric Raymond, Guido Rindi, Andrea Rockall, Philippe Ruszniewski, Ramón Salazar, Aldo Scarpa, Eva Sedláčková, Anders Sundin, Christos Toumpanakis, Marie‐Pierre Vullierme, Wolfgang Weber, Bertram Wiedenmann, Zeng Zheng-Pei - Annals of Oncology 2015 cited by 699

  6. Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma

    Authors: Mohamed Bouattour, Éric Raymond, Shukui Qin, Ann‐Lii Cheng, Uz Stammberger, Giuseppe Locatelli, Sandrine Faivre - Hepatology 2017 cited by 261

  7. Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

    Authors: Sandrine Faivre, Armando Santoro, Robin Kate Kelley, Ed Gane, Charlotte Costentin, Ivelina Gueorguieva, Claire Smith, Ann Cleverly, Michael Lahn, Éric Raymond, Karim A. Benhadji, Gianluigi Giannelli - Liver International 2019 cited by 143

  8. Oxaliplatin: A review of preclinical and clinical studies

    Authors: Éric Raymond, Stephen G. Chaney, A. Taamma, Esteban Cvitkovic - Annals of Oncology 1998 cited by 636

  9. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas

    Authors: Rocio García‐Carbonero, Halfdan Sørbye, Éric Baudin, Éric Raymond, Bertram Wiedenmann, Bruno Niederle, Eva Sedláčková, Christos Toumpanakis, Martin Anlauf, Jarosław B. Ćwikła, Martyn Caplin, Dermot O’Toole, Aurel Perren, all other Vienna Consensus Conference participants - Neuroendocrinology 2016 cited by 606

  10. Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

    Authors: Ann‐Lii Cheng, Yoon‐Koo Kang, Deng‐Yn Lin, Joong‐Won Park, Masatoshi Kudo, Shukui Qin, Hyun Cheol Chung, Xiangqun Song, Jianming Xu, Guido Poggi, Masao Omata, Susan Pitman Lowenthal, Silvana Lanzalone, Liqiang Yang, María José Lechuga, Éric Raymond - Journal of Clinical Oncology 2013 cited by 774

  11. Molecular basis for sunitinib efficacy and future clinical development

    Authors: Sandrine Faivre, George D. Demetri, William Q. Sargent, Éric Raymond - Nature Reviews Drug Discovery 2007 cited by 712

  12. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)

    Authors: Christophe Le Tourneau, Éric Raymond, Sandrine Faivre - Therapeutics and Clinical Risk Management 2007 cited by 242

  13. MEK in cancer and cancer therapy

    Authors: Cindy Neuzillet, Annemilaï Tijeras‐Raballand, Louis de Mestier, Jérôme Cros, Sandrine Faivre, Éric Raymond - Pharmacology & Therapeutics 2013 cited by 265

  14. Current development of mTOR inhibitors as anticancer agents

    Authors: Sandrine Faivre, Guido Kroemer, Éric Raymond - Nature Reviews Drug Discovery 2006 cited by 995

  15. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)

    Authors: Angélique Vienot, Marion Jacquin, Magali Rebucci-Peixoto, Dimitri Pureur, François Ghiringhelli, Eric Assénat, Pascal Hammel, Olivier Rosmorduc, Morgane Stouvenot, Manon Allaire, Mohamed Bouattour, Hélène Regnault, Serge Fratté, Éric Raymond, Émilie Soularue, Stéphanie Husson-Wetzel, Vincent Di Martino, Allison Muller, Anne‐Laure Clairet, Christine Fagnoni-Legat, Olivier Adotévi, Aurélia Meurisse, Déwi Vernerey, Christophe Borg - BMC Cancer 2023 cited by 22

  16. Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

    Authors: Sandrine Faivre, Catherine Delbaldo, Karina Vera, Caroline Robert, Stéphanie Lozahic, Nathalie Lassau, Carlo L. Bello, Samuel E. DePrimo, Nicoletta Brega, Giorgio Massimini, Jean‐Pierre Armand, P. Scigalla, Éric Raymond - Journal of Clinical Oncology 2005 cited by 1,154

  17. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis

    Authors: Lucile Astorgues‐Xerri, María E. Riveiro, Annemilaï Tijeras‐Raballand, Maria Serova, Gabriel A. Rabinovich, Ivan Bièche, Michel Vidaud, Armand de Gramont, Mathieu Martinet, Esteban Cvitkovic, Sandrine Faivre, Éric Raymond - European Journal of Cancer 2014 cited by 137

  18. First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers

    Authors: James J. Harding, Ahmad Awada, Gaël S. Roth, Thomas Decaens, Philippe Merle, Nuria Kotecki, Chantal Dreyer, Christelle Ansaldi, Madani Rachid, Soraya Mezouar, Agnes Menut, Eloïne Bestion, Valérie Paradis, Philippe Halfon, Ghassan K. Abou‐Alfa, Éric Raymond - Liver Cancer 2022 cited by 30

  19. Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

    Authors: Christophe Le Tourneau, Sandrine Faivre, Valérie Laurence, Catherine Delbaldo, Karina Vera, Véronique Girre, Judy H. Chiao, Sian Armour, Sheelagh Frame, Simon R. Green, Athos Gianella-Borradori, Véronique Dièras, Éric Raymond - European Journal of Cancer 2010 cited by 167

  20. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas

    Authors: Stéphane Goutagny, Éric Raymond, Marina Esposito‐Farèse, Stéphanie Trunet, Christian Mawrin, Danièle Bernardeschi, Béatrice Larroque, Olivier Sterkers, Marco Giovannini, Michel Kalamarides - Journal of Neuro-Oncology 2015 cited by 118

  21. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer

    Authors: Eric Van Cutsem, Manuel Hidalgo, Jean‐Luc Canon, Teresa Macarulla, I. Bazin, Elena Poddubskaya, Nebojša Manojlović, Dejan Radenković, Chris Verslype, Éric Raymond, Antonio Cubillo, Armin Schueler, Charles Zhao, Pascal Hammel - International Journal of Cancer 2018 cited by 105

  22. Roscovitine and Other Purines as Kinase Inhibitors. From Starfish Oocytes to Clinical Trials

    Authors: Laurent Meijer, Éric Raymond - ChemInform 2003 cited by 350

  23. Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study

    Authors: Sandrine Faivre, Patricia Niccoli, Daniel Castellano, Juan W. Valle, Pascal Hammel, Jean‐Luc Raoul, Aaron I. Vinik, Eric Van Cutsem, Yu Jeong Bang, Seung‐Hoon Lee, Ivan Borbath, Catherine Lombard‐Bohas, Peter Metrakos, Denis Smith, J.-S. Chen, Philippe Ruszniewski, Jean‐François Seitz, Shem Patyna, Dongrui R. Lu, K. Jack Ishak, Éric Raymond - Annals of Oncology 2016 cited by 192

  24. Antitumor Agent Calixarene 0118 Targets Human Galectin-1 as an Allosteric Inhibitor of Carbohydrate Binding

    Authors: Ruud P.M. Dings, Michelle C. Miller, Irina V. Nesmelova, Lucile Astorgues‐Xerri, Nigam Kumar, Maria Serova, Xuimei Chen, Éric Raymond, Thomas R. Hoye, Kevin H. Mayo - Journal of Medicinal Chemistry 2012 cited by 133